OrbiMed’s Juno Therapeutics, Inc. JUNO Stock Holding History

OrbiMed’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,835,188	Closed	-$83.9M	–	156
2017 Q4	$83.9M	Sell	1,835,188 -206,420	-10%	-$10.3M	1.06%	28
2017 Q3	$91.6M	Buy	2,041,608 +1,126,400	+123%	+$38.4M	0.88%	34
2017 Q2	$27.4M	Buy	+915,208	New	+$22.6M	0.29%	74

Other funds holding JUNO

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

OrbiMed's JUNO Position: Q1 2018 in Review

OrbiMed sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 1,835,188 shares — an estimated $83.9M sold.

OrbiMed first reported a position in JUNO in Q2 2017 and held it in 3 quarters. The position peaked at $91.6M in Q3 2017. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

OrbiMed reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
OrbiMed sold 1,835,188 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $83.9M.
OrbiMed first reported a position in Juno Therapeutics, Inc. in Q2 2017 and held it in 3 quarters.
OrbiMed's Juno Therapeutics, Inc. position peaked at $91.6M in Q3 2017.
2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on OrbiMed's 13F filing for Q1 2018, filed 15 May 2018.